UNSPSC 51162655: Zipeprol

This classification denotes an antitussive agent with the molecular formula C23H32N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G5MUV8139H, chemically known as 1-piperazineethanol, alpha-(alpha-methoxybenzyl)-4-(beta-methoxyphenethyl)-, dihydrochloride but more generally known as zipeprol, which bears US NIH Compound Identifier 36909. European Medicines Agency schedules Zipeprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00167MIG.

UNSPSC 51162655 Zipeprol is a Commodity code representing pharmaceutical products, specifically opioid antagonists and related medications, that state and local governments procure for public health, emergency response, and community health initiatives. Recent solicitations show state and local agencies buying naloxone and drug deactivation systems for harm reduction and overdose response programs, as well as participating in multi-state cooperative purchasing agreements for generic pharmaceuticals and over-the-counter products distributed across government facilities. Issuing bodies include county health departments (Seminole County, Florida), state procurement offices administering cooperative purchasing vehicles (Minnesota Department of Administration), and multi-jurisdictional alliances coordinating pharmaceutical supply across member states and localities. The work involves competitive bidding for pharmaceutical products with specific regulatory compliance requirements including FDA certification, Drug Supply Chain Security Act (DSCSA) adherence, current Good Manufacturing Practices (cGMP) compliance, and E-Verify authorization. Vendors must maintain authorized wholesaler relationships, manage electronic data interchange systems, and meet insurance thresholds including commercial general liability coverage of up to $5,000,000 per occurrence for larger cooperative agreements.

Geographic activity centers on Florida and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinating procurement across participating states including Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, through competitive bidding with a two-year initial term and optional one-year renewal. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products through MMCAP, with proposals due March 26, 2026, and awarded vendor lists provided to authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC) by May 15, 2026, for July 1, 2026, contract effectiveness. Evaluation criteria for the MMCAP RFP weighted price competitiveness at 75 percent, fixed pricing at 10 percent, and administrative and technical compliance factors at 15 percent combined, with contracts structured for two-year terms and optional extensions.